Stockreport

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

ChromaDex Corporation  (CDXC) 
NASDAQ:AMEX Investor Relations: investors.chromadex.com
PDF NR improved the six-minute walking distance and treadmill walking time for those with PAD LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global auth [Read more]